GNAS and cancer: Regarding TP53 aberration in the malignant transformation of FD, it is notable that its coexistence with GNAS activating mutations has been reported in other malignant tumours, including colorectal adenocarcinoma, oesophageal squamous cell carcinoma, pancreatic adenocarcinoma and non‐small‐cell lung cancer (Table 5, data from TCGA database).